Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

Prajwal Boddu, Preetesh Jain, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Farhad Ravandi, Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% and 96%, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.

Original languageEnglish (US)
Pages (from-to)3172-3180
Number of pages9
JournalLeukemia and Lymphoma
Volume60
Issue number13
DOIs
StatePublished - Nov 10 2019
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Therapeutics
ponatinib
Blood Vessels
Outcome Assessment (Health Care)

Keywords

  • chronic myeloid leukemia
  • chronic phase
  • frontline
  • outcomes
  • Ponatinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Boddu, P., Jain, P., Borthakur, G., Verstovsek, S., Garcia-Manero, G., Daver, N., ... Kantarjian, H. (2019). Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia and Lymphoma, 60(13), 3172-3180. https://doi.org/10.1080/10428194.2019.1617862

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. / Boddu, Prajwal; Jain, Preetesh; Borthakur, Gautam; Verstovsek, Srdan; Garcia-Manero, Guillermo; Daver, Naval; Kadia, Tapan; Ravandi, Farhad; Jabbour, Elias; Cortes, Jorge; Kantarjian, Hagop.

In: Leukemia and Lymphoma, Vol. 60, No. 13, 10.11.2019, p. 3172-3180.

Research output: Contribution to journalArticle

Boddu, P, Jain, P, Borthakur, G, Verstovsek, S, Garcia-Manero, G, Daver, N, Kadia, T, Ravandi, F, Jabbour, E, Cortes, J & Kantarjian, H 2019, 'Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy', Leukemia and Lymphoma, vol. 60, no. 13, pp. 3172-3180. https://doi.org/10.1080/10428194.2019.1617862
Boddu, Prajwal ; Jain, Preetesh ; Borthakur, Gautam ; Verstovsek, Srdan ; Garcia-Manero, Guillermo ; Daver, Naval ; Kadia, Tapan ; Ravandi, Farhad ; Jabbour, Elias ; Cortes, Jorge ; Kantarjian, Hagop. / Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. In: Leukemia and Lymphoma. 2019 ; Vol. 60, No. 13. pp. 3172-3180.
@article{4f41ed1b807c4fba952b6d5b5d42ba8d,
title = "Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy",
abstract = "Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92{\%} and 96{\%}, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.",
keywords = "chronic myeloid leukemia, chronic phase, frontline, outcomes, Ponatinib",
author = "Prajwal Boddu and Preetesh Jain and Gautam Borthakur and Srdan Verstovsek and Guillermo Garcia-Manero and Naval Daver and Tapan Kadia and Farhad Ravandi and Elias Jabbour and Jorge Cortes and Hagop Kantarjian",
year = "2019",
month = "11",
day = "10",
doi = "10.1080/10428194.2019.1617862",
language = "English (US)",
volume = "60",
pages = "3172--3180",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "13",

}

TY - JOUR

T1 - Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

AU - Boddu, Prajwal

AU - Jain, Preetesh

AU - Borthakur, Gautam

AU - Verstovsek, Srdan

AU - Garcia-Manero, Guillermo

AU - Daver, Naval

AU - Kadia, Tapan

AU - Ravandi, Farhad

AU - Jabbour, Elias

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2019/11/10

Y1 - 2019/11/10

N2 - Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% and 96%, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.

AB - Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% and 96%, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.

KW - chronic myeloid leukemia

KW - chronic phase

KW - frontline

KW - outcomes

KW - Ponatinib

UR - http://www.scopus.com/inward/record.url?scp=85066911495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066911495&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1617862

DO - 10.1080/10428194.2019.1617862

M3 - Article

C2 - 31125272

AN - SCOPUS:85066911495

VL - 60

SP - 3172

EP - 3180

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 13

ER -